Stocktoria
LIXTE BIOTECHNOLOGY HOLDINGS, INC. LIXT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2007-09-21
LIXTE BIOTECHNOLOGY HOLDINGS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $254,919 | $726,232 | $898,100 | $1.3M | $1.7M |
| Operating income | -$5.1M | -$3.6M | -$5.1M | -$6.3M | -$6.7M |
| Interest expense | $9,158 | $16,821 | $16,233 | $8,875 | $7,414 |
| Income tax | $1,600 | — | — | — | — |
| Net income | -$6.1M | -$3.6M | -$5.1M | -$6.3M | -$6.7M |
| EPS (diluted) | $-1.26 | $-1.59 | $-2.66 | $-3.99 | — |
| Operating cash flow | -$3.1M | -$3.2M | -$4.3M | -$4.6M | -$4.1M |
| Cash & equivalents | — | — | $4.2M | $5.4M | $4.8M |
| Total assets | $12.7M | $1.1M | $4.3M | $5.6M | $5.1M |
| Total liabilities | $1.8M | $318,284 | — | — | — |
| Shareholders' equity | $11.0M | $827,219 | $4.0M | $5.2M | $4.8M |
Source: SEC EDGAR filings · CIK 0001335105 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.